

Implications of Recent Data Sets for the Current and Future Management of Lung Cancer

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

- 1. Which of the following adverse events of special interest was most commonly reported by patients receiving datopotamab deruxtecan for previously treated advanced non-small cell lung cancer (NSCLC) in the Phase III TROPION-Lung01 trial?**
 - Hyperphosphatemia
 - Guillain-Barré syndrome
 - Myopericarditis
 - d. Stomatitis**
 - I'm not sure
- 2. Which of the following proteins is targeted by the investigational antibody-drug conjugate ifinatamab deruxtecan?**
 - HER2
 - b. B7-H3**
 - CDC42
 - RET
 - I'm not sure
- 3. Which of the following adverse events of any grade was most commonly observed in patients receiving amivantamab with lazertinib as first-line therapy for advanced NSCLC and an EGFR mutation in the Phase III MARIPOSA trial?**
 - Confusion
 - b. Paronychia**
 - Dry mouth
 - Blurred vision
 - I'm not sure
- 4. Which of the following outcomes was observed with the addition of chemotherapy to first-line osimertinib for patients with advanced NSCLC and EGFR mutations in the Phase III FLAURA2 trial?**
 - Improved progression-free survival
 - Improved intracranial ORR (objective response rate)
 - Increased toxicity
 - d. All of the above**
 - I'm not sure
- 5. An overall survival benefit was observed with adjuvant osimertinib in which of the following patients with completely resected NSCLC and an EGFR mutation?**
 - Patients with Stage IB disease
 - Patients with Stage II disease
 - Patients with Stage IIIA disease
 - d. All of the above**
 - I'm not sure